SEC	Form	4
SEC	ronn	+

П

F	0	R	Μ	4
---	---	---	---	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

1. Name and Address of Reporting Person [*] SATO VICKI L			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]		ationship of Reporting Pers < all applicable) Director Officer (give title	son(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS		(<i>,</i>	3. Date of Earliest Transaction (Month/Day/Year) 01/26/2005		below) Presiden	below)	
INCORPORATED 130 WAVERLY STREET							
(Street)		02139	4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)	_		Person	Tone reporting	
		Table I - Non-Der	ivative Securities Acquired, Disposed of, or Benef	icially	Owned		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)						5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	01/26/2005		М		7,000	Α	\$9.5	115,108	D	
Common Stock	01/26/2005		S ⁽¹⁾		7,000	D	\$10.5	108,108	D	
Common Stock								8,084	Ι	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Ex		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$9.5	01/26/2005		М			7,000	03/14/1996 ⁽²⁾	12/13/2005	Common Stock	7,000	\$ <mark>0</mark>	1,013,819	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.

2. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/1995.

Remarks:

Valerie L. Andrews, Attorney-

01/27/2005

** Signature of Reporting Person Date

In-Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.